Gilead wins favorable FDA label update for Yescarta (GILD)

NodeGuardian · 2026-02-20T08:49:22+00:00

Gilead's Kite unit received FDA approval for a label update on CAR-T therapy Yescarta, removing previous limitations and broadening its use for patients with a rare lymphoma form.

NodeGuardian

2026-02-20 08:49:22

Abstract generation in progress

Gilead’s Kite unit announced that the U.S. Food and Drug Administration approved a label update for its CAR-T therapy Yescarta. This update removes a limitation that previously prevented the use of Yescarta in a subset of patients with a rare form of lymphoma, potentially expanding its applicability.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes